Windward Bio Announces Pricing of Initial Public Offering

Rhea-AI Summary

Windward Bio Group (WWB) priced its initial public offering of common shares at $17.00 per share, alongside a concurrent private placement. The IPO comprises 10,294,117 common shares, all offered by Windward. Combined gross proceeds are expected to be $225.0 million, before fees and expenses and excluding the underwriters’ option.

Sanofi Foreign Participations will purchase 1,532,691 common shares and pre-funded warrants to purchase 1,408,485 common shares for $50.0 million. Underwriters have a 30-day option to purchase up to 1,544,117 additional shares. Trading on the Nasdaq Global Select Market is expected to begin November 13, 2026. The IPO is expected to close November 16, 2026, when the private placement is also scheduled to close.

1 point · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 4 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point. Forward-looking: it has not happened yet and may not happen.Combined IPO and private placement gross proceeds are expected at $225.0 million, before expenses and excluding the underwriters’ option.

Negative

• Major point. Forward-looking: it has not happened yet and may not happen.IPO issuance of 10,294,117 common shares at $17.00 each dilutes existing holders.
• Minor point. Forward-looking: it has not happened yet and may not happen.Sanofi’s $50.0 million placement adds 1,532,691 shares and pre-funded warrants for 1,408,485 shares, diluting holders.
• Minor point. Forward-looking: it has not happened yet and may not happen.Underwriters’ 30-day option permits up to 1,544,117 additional shares at the IPO price, less underwriting discounts and commissions.
• Minor pointPrivate placement closing is conditional on completion of the IPO.

News Explained

The private placement is scheduled to close with the priced IPO but can close only if the IPO is consummated; the IPO can close without the placement, so proceeding with the IPO does not ensure the additional $50.0 million placement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BASEL, Switzerland, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Windward Bio Group AG (“Windward”) (Nasdaq: WWB), a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, today announced the pricing of its initial public offering of 10,294,117 common shares at a public offering price of $17.00 per share. In addition, Windward has granted the underwriters a 30-day option to purchase up to an additional 1,544,117 common shares at the initial public offering price, less the underwriting discounts and commissions. The gross proceeds to Windward from the initial public offering and the concurrent private placement (see below), without giving effect to the underwriters’ option to purchase additional shares and before deducting underwriting discounts and commissions and offering expenses, are expected to be $225.0 million. All of the common shares are being offered by Windward.

In addition to the common shares sold in the initial public offering, Windward announced a concurrent sale of 1,532,691 common shares and pre-funded warrants to purchase 1,408,485 common shares, in each case at the initial public offering price per common share, in a private placement to Sanofi Foreign Participations B.V. for an aggregate purchase price of $50.0 million. The sale of the common shares and pre-funded warrants will not be registered under the Securities Act of 1933, as amended (the “Securities Act”).

Windward’s shares are expected to begin trading on the Nasdaq Global Select Market on November 13, 2026 under the symbol “WWB.” The offering is expected to close on November 16, 2026, subject to customary closing conditions.

Jefferies, TD Cowen, Piper Sandler and UBS Investment Bank are acting as joint book-running managers for the offering.

A registration statement relating to the shares being sold in the initial public offering has been filed with the U.S. Securities and Exchange Commission and was declared effective on November 12, 2026. The offering of the shares is being made only by means of a prospectus forming part of the effective registration statement relating to these shares. Copies of the final prospectus, when available, may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at 877-821-7388, or by email at prospectus_department@jefferies.com; TD Securities (USA) LLC, Attn: c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, by telephone at (800) 747-3924, or by email at prospectus@psc.com or UBS Securities LLC, Attention: Prospectus Department, 11 Madison Avenue, New York, New York 10010, by email at ol-prospectus-request@ubs.com.

The concurrent private placement is also scheduled to close on November 16, 2026, subject to the satisfaction of customary closing conditions. The closing of the private placement is contingent and conditioned on consummation of the initial public offering. However, the closing of the initial public offering is not contingent on the consummation of the concurrent private placement.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

For media and investor inquiries:
Noel Kurdi
SVP, Investor Relations and Communications
investors@windwardbio.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Windward Bio’s IPO price and expected fundraising amount?

Windward priced 10,294,117 common shares at $17.00 per share. Combined gross proceeds from the IPO and concurrent private placement are expected to be $225.0 million, before underwriting discounts, commissions and offering expenses, and excluding the underwriters’ option.

When will Windward Bio shares begin trading and the IPO close?

Windward shares are expected to begin trading on the Nasdaq Global Select Market on November 13, 2026, under WWB. The IPO is expected to close November 16, 2026, subject to customary closing conditions.

Does Windward Bio’s IPO depend on the Sanofi private placement closing?

The IPO closing is not contingent on the private placement. The reverse condition does apply: the concurrent private placement can close only if the IPO is completed. The private placement is scheduled to close November 16, 2026, subject to customary closing conditions.